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Background/Aims: This study aimed to assess the validity and diagnostic performance of the 
imaging criteria of Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) 2018 
using magnetic resonance imaging (MRI) in high-risk patients for HCC.
Methods: This retrospective study included 142 treatment-naïve patients (81 patients 
who underwent MRI with extracellular contrast agent and 61 who underwent MRI with 
hepatobiliary agent; 183 lesions including 149 HCCs) with a high risk of HCC who underwent 
multiphasic contrast-enhanced MRI from January to December 2015. All lesions were 
categorized according to the KLCA-NCC 2018 imaging diagnostic criteria by two readers, and 
per-lesion diagnostic performances were compared.
Results: According to the KLCA-NCC 2018, none (0%) of the 13 benign category lesions, 11 
(44.0%) of 25 indeterminate category lesions, 15 (93.8%) of 16 probable HCC category lesions, 
and 97 (99.0%) of 98 definite HCC category lesions were ultimately diagnosed as HCCs. The 
sensitivity and specificity of definite HCC category were 65.1% and 97.1%, respectively, and 
those of the combination of definite and probable HCC categories were 75.2% and 94.1%, 
respectively. The sensitivity of the combination of definite and probable HCC categories was 
significantly higher than that of definite HCC (P<0.001), but the specificity was not significantly 
lower (P>0.999).
Conclusions: The noninvasive imaging diagnosis of KLCA-NCC 2018 on MRI is reliable and 
useful for diagnosing HCC in high-risk patients. Combining definite and probable HCC categories 
of KLCA-NCC 2018 improves the sensitivity while maintaining a high specificity. (J Liver Cancer 
2020;20:120-127)
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Hepatocellular carcinoma (HCC) is the most common 
primary hepatic malignancy.1 HCC is the only malignancy 
that can be diagnosed based on imaging without the need for 
pathologic confirmation in high-risk patients. Thus, reliable 
noninvasive imaging criteria are essential.2-4
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The Korean Liver Cancer Study Group (KLCSG)-National 
Cancer Center (NCC) Korea practice guidelines for HCC 
were first developed in 2003, and subsequently revised in 
2009, 2014, and 2018.5,6 They provide diagnosis and treat-
ment guidelines specific to the Asian population, particularly 
Korean.5,6 In contrast to the previous version of the KLCSG-
NCC Korea practice guidelines, the recently updated Korean 
Liver Cancer Association (KLCA)-NCC 2018 practice guide-
line for the imaging diagnosis of HCC has been revised into a 
non-binary decision algorithm that addresses the full spec-
trum of liver lesions, ranging from benign to malignant.7 
KLCA-NCC 2018 categorizes a lesion as benign, indetermi-
nate, probable HCC, definite HCC, or targetoid appearance 
based on major, ancillary, and targetoid imaging features.6,8
However, to the best of our knowledge, external validation 
of the imaging criteria of KLCA-NCC 2018 has not been 
published. Therefore, the aim of this study was to assess the 
validity and diagnostic performance of the imaging criteria of 
KLCA-NCC 2018 using magnetic resonance imaging (MRI) 
in high-risk patients for HCC.
METHODS
This retrospective study was approved by the institutional 
review board of Severance Hospital (IRB number 4-2019-
1218), and the requirement for informed consent was 
waived. 
1. Study population
We retrospectively searched our institution’s databases for 
a clinical cohort of HCC surveillance and identified 1,211 
patients who underwent MRI for diagnostic workup between 
January 2015 and December 2015. The inclusion criteria 
were treatment-naïve adult patients (≥18 years) who were at 
a high risk for HCC according to the KLCA-NCC 2018 with 
at least one and up to five hepatic observations (each ≥1 
cm) on MRI. We excluded patients with insufficient final di-
agnosis such as unknown final diagnosis of malignancy as a 
result of immediate locoregional therapy or insufficient fol-
low-up (<2 years) for benign lesions to determine size stabil-
ity. We did not include observations such as hepatic cysts, 
perfusion alteration, hepatic fat deposition or sparing, hyper-
trophic pseudomass, confluent fibrosis, and focal scar. A to-
tal of 142 patients (mean age, 57.2 years; 104 men and 38 
women) with 183 lesions (149 HCCs, 6 non-HCC malignan-
cies, and 28 benign lesions) met our criteria and were includ-
ed in this study. 
2. MRI examination
MRI was performed using one of the three 3.0-T systems 
(Magnetom Trio Tim, Siemens Medical Solutions, Erlangen, 
Germany; Intera Achieva, Ingenia, or Ingenia CX, Philips 
Medical Systems, Best, The Netherlands; and Discovery MR 
750w, GE Medical Systems, Waukesha, WI, USA) or a 1.5-T 
system (Intera Achieva, Philips Medical Systems, Best, The 
Netherlands). The protocol included the acquisition of dual-
echo T1-weighted gradient-echo images (in-phase and op-
posed-phase), T1-weighted three-dimensional gradient-echo 
images with dynamic contrast-enhancement, navigator-trig-
gered single or multi-shot T2-weighted images, and diffusion-
weighted images at b-values of 0 or 50, 400, and 800 s/mm2. 
Dynamic T1-weighted imaging was performed before and af-
ter administering one of the two extracellular contrast agents 
(ECAs) (gadoterate meglumine, Dotarem, Guerbet SA, Aul-
nay-sous-Bois, France; and gadopentetate dimeglumine, 
Magnevist, Bayer Pharma AG, Berlin, Germany) or a hepato-
biliary agent (HBA) (gadoxetate disodium, Primovist, Bayer 
Pharma AG): a bolus injection of 0.2 mL/kg gadoterate meglu-
mine or gadopentetate dimeglumine (n=81) at a rate of 2.0 
mL/s, or 0.1 mL/kg gadoxetate disodium (n=61) at a rate of 
1.0 mL/s, followed by a 20-mL saline flush using a power in-
jector. Arterial phase scanning was initiated using the test-bo-
lus or bolus-tracking technique, and the portal venous phase 
(PVP) (60 s), 3-min delayed phase (DP; transitional phase on 
HBA-MRI), and 20-min hepatobiliary phase (HBP) images 
(only after HBA administration) were obtained.
3. Image analysis
Two board-certified abdominal radiologists independently 
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reviewed all images. They were blinded to the final diagnoses 
of all lesions but knew that the study population comprised 
patients at high risk for HCC. According to the KLCA-NCC 
2018, the readers assessed the presence or absence of major 
and ancillary imaging features and targetoid appearance.6,8 
Each lesion was categorized as definite HCC, probable HCC, 
indeterminate, benign, or targetoid appearance.6,8 Definite 
HCC was defined as arterial phase hyperenhancement with 
washout in the PVP, DP, or HBP.6,8 In a lesion with some but 
not all of the major imaging features of HCC, probable HCC 
was assigned only when the lesion fulfilled at least one item 
from each of the following two categories of ancillary imag-
ing features: favoring malignancy in general, and favoring 
HCC in particular.6,8 When the imaging diagnosis was incon-
clusive, a lesion was defined as indeterminate.6,8 A lesion that 
fulfilled at least one of the ancillary features favoring benigni-
ty was classified as a benign lesion.6,8 Targetoid appearance 
was evaluated on diffusion-weighted imaging (DWI) or con-
trast-enhanced sequences. After an independent categoriza-
tion, inter-reader agreement was evaluated. In cases of dis-
crepancies between the two readers, the final category was 
determined by consensus discussion.
4. Reference standards
The diagnoses of HCCs and non-HCC malignancies were 
confirmed by pathology, including surgical resection 
(n=142) or explant for transplantation (n=13). Benign diag-
noses were obtained through pathology (n=1) or typical im-
aging features and stability at imaging for at least 2 years 
(n=27). The mean interval between MRI and pathological 
confirmation was 19.2 (range, 1-58) days.
5. Statistical analysis
All analyses were performed on a per-lesion basis. Per-le-
sion estimates of diagnostic performances (sensitivity, speci-
ficity, positive predictive value [PPV], and negative predic-
tive value [NPV]) were calculated. The sensitivities and 
specificities of definite HCC category and the combination of 
definite and probable HCC categories of KLCA-NCC 2018 
were compared using the McNemar’s test. The χ2 test was 
used to compare the diagnostic performances of definite 
HCC and the combination of definite and probable HCC of 
KLCA-NCC 2018 between the two independent ECA-MRI 
and HBA-MRI groups. Inter-reader agreement was evaluated 
using Cohen κ coefficient. The κ-value (the level of agree-
ment) was defined as follows: poor, 0.00-0.20; fair, 0.21-0.40; 
moderate, 0.41-0.60; good, 0.61-0.80; and excellent, 0.81-
1.00. Statistical analyses were performed using MedCalc ver-
sion 16.2.1 (MedCalc Software, Ostend, Belgium). 
Table 1. Characteristics of the patients and lesions
Characteristic Value
Patients n=142
  Sex (male) 104 (73.2)
  Age (years) 57.2±9.9 (29-78)
  Etiology of liver disease
    Hepatitis B 119 (83.8)
    Hepatitis C 8 (5.6)
    Alcohol 12 (8.5)
    Others 3 (2.1)
Lesions n=183
  Lesion size (mm) 30.2±23.9 (10-200)
  MRI contrast
    ECA-MRI 104 (56.8)
    HBA-MRI 79 (43.2)
  Final diagnosis
    HCC 149 (81.4)
    Non-HCC malignancy
      Combined hepatocellular-
cholangiocarcinoma
4 (2.2)
      Intrahepatic cholangiocarcinoma 2 (1.1)
    Benign lesion
      Hemangioma 6 (3.3)
      Focal nodular hyperplasia-like nodule 7 (3.8)
      Regenerative nodule 5 (2.7)
      Dysplastic nodule 10 (5.5)
Values are presented as mean±standard deviation (range) or number 
(%) unless otherwise indicated.
MRI, magnetic resonance imaging; ECA, extracellular contrast agent; 
HBA, hepatobiliary agent; HCC, hepatocellular carcinoma.
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RESULTS
1. Patients and lesions
The characteristics of the patients and lesions are summa-
rized in Table 1. Our study included 81 patients with 104 le-
sions who underwent ECA-MRI, and 61 patients with 79 le-
sions who underwent HBA-MRI. Hepatitis B (83.8%) was 
the most common etiology of liver disease. The 183 lesions 
comprised 149 (81.4%) HCCs, 6 (3.3%) non-HCC malig-
nancies, and 28 (15.3%) benign lesions.
2.  Lesion categorization according to the KLCA-
NCC 2018
Lesion categorization according to the KLCA-NCC 2018 is 
summarized in Table 2. Thirteen (7.1%) lesions were classi-
fied as benign, 25 (13.7%) as indeterminate, 16 (8.7%) as 
probable HCC, and 98 (53.6%) as definite HCC. Thirty-one 
(16.9%) lesions were categorized as targetoid appearance. 
All lesions classified as benign category on MRI were final-
ly diagnosed as benign lesions. Eleven (44.0%) of 25 lesions 
classified as indeterminate category were ultimately diag-
nosed as HCCs. Fifteen (93.8%) of 16 lesions classified as 
probable HCC were finally diagnosed as HCCs. Ninety-seven 
(99.0%) of 98 lesions classified as definite HCC were ulti-
mately diagnosed as HCCs.
3.  Diagnostic performances of KLCA-NCC 2018 
on MRI for HCC 
The diagnostic performances of KLCA-NCC 2018 on MRI 
for HCC are summarized in Table 3. Considering only le-
sions classified as definite HCC, the sensitivity, specificity, 
PPV, and NPV were 65.1%, 97.1%, 99.0%, and 38.8%, re-
spectively (Fig. 1, 2). There was one false-positive diagnosis 
of KLCA-NCC 2018 in the definite HCC category, which 
was a combined hepatocellular-cholangiocarcinoma. Con-
sidering definite and probable HCC categories, the sensitivi-
ty, specificity, PPV, and NPV were 75.2%, 94.1%, 98.3%, 





HCC Non-HCC malignancy Benign lesions
Benign 13 0 0 13
Indeterminate  25 11 0 14
Probable HCC 16 15 0 1
Definite HCC 98 97 1 0
Targetoid appearance 31 26 5 0
KLCA-NCC, Korean Liver Cancer Association-National Cancer Center; HCC, hepatocellular carcinoma.
Table 3. Diagnostic performances of definite HCC and definite and probable HCC categories according to the KLCA-NCC 2018
Definite HCC of KLCA-NCC 2018 
(95% CI)
Definite+probable HCC of KLCA-
NCC 2018 (95% CI)
P-value*
Sensitivity 65.1 (56.9-72.7) 75.2 (67.4-81.9) <0.001
Specificity 97.1 (84.7-99.9) 94.1 (80.3-99.3) >0.999
PPV 99.0 (94.5-99.9) 98.3 (93.8-99.8) -
NPV 38.8 (28.4-50.0) 46.4 (34.3-58.8) -
HCC, hepatocellular carcinoma; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center; CI, confidence interval; PPV, positive 
predictive value; NPV, negative predictive value.
*P-values between definite HCC category and the combination of definite and probable HCC categories of KLCA-NCC 2018 by using the 
McNemar’s test.
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and 46.4% in diagnosing HCC, respectively (Fig. 3). The 
sensitivity of the combination of definite HCC and probable 
HCC was significantly higher than that of definite HCC 
(P <0.001), but the specificity was not significantly lower 
(P>0.999).
4.  Comparison of diagnostic performances of 
ECA-MRI and HBA-MRI for definite HCC and 
definite and probable HCC categories ac-
cording to the KLCA-NCC 2018
Table 4 presents the comparison of diagnostic perfor-
mances of ECA-MRI and HBA-MRI for definite HCC and 
definite and probable HCC categories according to the 
Figure 1. Hepatocellular carcinoma (HCC) in a 50-year-old man with chronic hepatitis B. In the arterial (A), portal venous (B), and delayed phase (C) 
images after the administration of extracellular contrast agent, a 47-mm liver mass (arrows) shows arterial phase hyperenhancement with washout in 
the delayed phase. The mass was categorized as definite HCC according to the Korean Liver Cancer Association-National Cancer Center 2018 criteria.
A B C
Figure 2. Hepatocellular carcinoma (HCC) in a 42-year-old woman with chronic hepatitis B. In the arterial (A), portal venous (B), and hepatobiliary 
phase (C) images after the administration of hepatobiliary agent, a 54-mm liver mass (arrows) shows arterial phase hyperenhancement with washout 
in the portal venous and hepatobiliary phases. The mass was categorized as definite HCC according to the Korean Liver Cancer Association-National 
Cancer Center 2018 criteria.
A B C
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KLCA-NCC 2018. In definite HCC category of KLCA-NCC 
2018, the sensitivity, specificity, PPV, and NPV were 60.5%, 
95.7%, 98.0%, and 40.7% for ECA-MRI, and 70.6%, 100%, 
100%, and 35.5% for HBA-MRI, respectively. No statistically 
significant differences in the sensitivity, specificity, PPV, and 
NPV were found for definite HCC category between ECA-
MRI and HBA-MRI (P>0.05 for all).
When combining definite HCC and probable HCC cate-
gories, the diagnostic performances of ECA-MRI and HBA-
MRI did not significantly differ, with a sensitivity, specificity, 
PPV, and NPV of 74.1%, 95.7%, 98.4%, and 51.2% for 
ECA-MRI, respectively, and 76.5%, 90.9%, 98.1%, and 
38.5% for HBA-MRI, respectively (P>0.05 for all).
Table 4. Comparison of diagnostic performances of ECA-MRI and HBA-MRI for definite HCC and definite and probable HCC categories according 
to the KLCA-NCC 2018 
ECA-MRI (95% CI) HBA-MRI (95% CI) P-value*
Definite HCC of KLCA-NCC 2018
  Sensitivity 60.5 (49.0-71.2) 70.6 (58.3-81.0) 0.198 
  Specificity 95.7 (78.1-99.9) 100 (71.5-100) 0.483 
  PPV 98.0 (89.4-99.9) 100 (92.6-100) 0.325 
  NPV 40.7 (27.6-55.0) 35.5 (19.2-54.6) 0.632 
Definite+probable HCC of KLCA-NCC 2018 
  Sensitivity 74.1 (63.1-83.2) 76.5 (64.6-85.9) 0.736 
  Specificity 95.7 (78.1-99.9) 90.9 (58.7-99.8) 0.582 
  PPV 98.4 (91.2-99.9) 98.1 (89.9-99.9) 0.920 
  NPV 51.2 (35.5-66.7) 38.5 (20.2-59.4) 0.305
ECA, extracellular contrast agent; MRI, magnetic resonance imaging; HBA, hepatobiliary agent; HCC, hepatocellular carcinoma; KLCA-NCC, Korean 
Liver Cancer Association-National Cancer Center; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.
*P-values between ECA-MRI and HBA-MRI by using the χ2 test.
Figure 3. Hepatocellular carcinoma (HCC) in a 57-year-old man with chronic hepatitis B. In the arterial (A) and hepatobiliary phase (B) images after 
the administration of hepatobiliary agent, a 50-mm liver mass (arrows) shows washout in the hepatobiliary phase without arterial phase 
hyperenhancement. Non-enhancing capsule is seen. On T2-weighted image (C), the mass demonstrates mild-to-moderate T2 hyperintensity. The 
mass was categorized as probable HCC according to the Korean Liver Cancer Association-National Cancer Center 2018 criteria.
A B C
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5. Inter-reader agreement
The inter-reader agreement for categorization of the le-
sions according to the KLCA-NCC 2018 was excellent 
(κ=0.91, 95% confidence interval, 0.87-0.95).
DISCUSSION
Our results demonstrated that noninvasive imaging diag-
nosis according to the KLCA-NCC 2018 on MRI is reliable 
and useful for diagnosing HCC in high-risk patients, provid-
ing a stratified probability of HCC and showing a high speci-
ficity and PPV for probable HCC and definite HCC catego-
ries. When combining definite HCC and probable HCC 
categories for the diagnosis of HCC, sensitivity was substan-
tially increased, while maintaining the specificity.
In our study, no HCC diagnosis was reported for the be-
nign category of KLCA-NCC 2018 imaging criteria, which 
reflects well-defined imaging features for benignity. For the 
indeterminate category, the proportion of HCC was 44.0%. 
Because of the substantial probability of HCC, lesions in the 
indeterminate category should be closely followed up or be 
considered for biopsy. The proportion of HCC was 93.8% 
for the probable HCC category and 99% for the definite 
HCC category. These results demonstrate that the imaging 
criteria of KLCA-NCC 2018 could provide a stratified proba-
bility for HCC.
The present study confirmed the high specificity for HCC 
diagnosis using the KLCA-NCC 2018 imaging criteria. The 
diagnostic criteria for HCC according to the KLCA-NCC 
2018, may have a high specificity by excluding hemangiomas 
or other malignancies, based on ancillary features favoring 
benignity such as marked T2 hyperintensity or targetoid ap-
pearance on DWI or contrast-enhanced sequences prior to 
the application of major imaging features.6,8 While the defi-
nite HCC category of KLCA-NCC 2018 shows a suboptimal 
sensitivity, the combination of definite and probable HCC 
categories provides improved sensitivity while maintaining a 
high specificity. Based on the KLCA-NCC 2018 criteria, a le-
sion classified as probable HCC requires at least one item 
from each of the two categories of ancillary imaging features 
(favoring malignancy in general and favoring HCC in partic-
ular);6,8 thus, it may prevent significant loss of specificity. 
In our study, there were no significant differences in the 
diagnostic performances of KLCA-NCC 2018 between ECA-
MRI and HBA-MRI. The updated versions of the imaging 
criteria for diagnosing HCC state that there is currently in-
sufficient evidence to recommend one contrast agent type 
over the other.2,3
This study has several limitations. First, due to the retro-
spective nature of this study, there may have been a potential 
selection bias. Second, this study enrolled patients from a 
single center in a chronic hepatitis B endemic area and thus, 
the generalizability of the results may be limited. Third, the 
composite clinical reference standard for the determination 
of benign lesions was used. However, pathologic confirma-
tion for highly suspected benign lesions is not recommended 
in clinical practice, and the application of a strict standard of 
reference (only pathology) for benign lesions may have re-
sulted in a confirmation bias. Finally, our use of consensus 
categorization may have increased our accuracy statistics 
compared with the clinical single-reader scenario. 
In conclusion, the noninvasive imaging diagnosis of 
KLCA-NCC 2018 on MRI is reliable and useful for diagnos-
ing HCC in high-risk patients. Combining definite and 
probable HCC categories of KLCA-NCC 2018 improves the 
sensitivity while maintaining a high specificity. 
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